There is no definitive clinical data on the survival rate of patients with intraductal breast cancer. However, if it is still at an early stage, patients can usually survive for more than 20 years after aggressive surgical treatment. Intraductal carcinoma is a relatively common type of breast cancer, named after the cancer cells that do not break through the myofibroblastic membrane of the duct wall. The malignancy of this type of cancer is relatively low and the prognosis is relatively good after surgical removal of the tumor. For early stage intraductal breast cancer, the surgical option is usually total mastectomy. If breast-conserving or breast-conserving combined with radiotherapy is chosen, a similar effect to total excision can be achieved, but there may be a certain chance of recurrence because the breast gland is still present. The survival of patients can usually reach more than 20 years, but there are no statistics on the exact survival rate. If intraductal breast cancer develops to an advanced stage, metastasis to other parts of the body will occur, and the patient’s body functions will deteriorate day by day, so the survival rate will be reduced accordingly. After the detection of intraductal breast cancer, it is recommended that patients should consult the oncology department in time and actively undergo surgery to improve the survival rate and quality of life.